|
 |
|
|
|
|
|
|
|
 |
|
 |
|
|
|
Global Network & Venture Partners
|
 |
|
Global Network
A Global Advantage
GlenRock leverages its global presence to facilitate business development for portfolio companies, and to identify new investment horizons in developing markets. With offices on three continents, GlenRock is excellently positioned to respond rapidly to global challenges, and provide significant added value to portfolio companies seeking international exposure.
GlenRock US
Headquartered in New York City, GlenRock Capital Advisers is an investment adviser led by Lawrence G. Graev and Anthony Hoberman. GlenRock Advisers is engaged in the business of advising institutional and other sophisticated investors with their alternative asset investment programs, primarily through investments in “best of breed” venture capital and buyout funds managed by independent third parties. The company's network of operational managers, technological innovators, legal professionals, financiers, and government officials allows GlenRock proprietary access to excellent and exclusive investment and advisory opportunities.
Visit the GlenRock US website..
Venture Partners
Rhodium
Rhodium is a private investment firm, based in Israel with an office in the U.S. and a broad network of international affiliates.
Our mission is to identify the most promising entrepreneurs and help them to build thriving companies.
Our focus is on high growth cutting-edge opportunities in the fields of Internet, New-media, Mobile and new technologies in general.
Our focus on diverse innovative technology start-up ventures stems from our passion and experience in the field, which enable us to bring substantial and sustainable value and commitment to entrepreneurs.
Our commitment is to support entrepreneurs and strengthen their ventures with our resources: funding, broad management expertise and an extensive valuable network of business contacts around the globe.
We stand to take an active role in most of our portfolio companies. We strategically invest in a handful of promising companies each year to allow us to be actively involved in creating the optimum environment for them to successfully transform into world class business ventures.
We are dedicated to value creation through each phase of the firm’s life-cycle, from early-stage to market leadership.
Regardless of the size of our initial investment, we like to continue to support our portfolio companies throughout their financing lifecycles.
Our passion is partnering with talented entrepreneurs to turn their ideas into industry-leading companies that will make a difference in our world.
Visit Rhodium's website
NGN Capital
Glenrock (Leon Recanati) a Venture Partner in NGN BioMed II, works with NGN Capital on fund raising from Israeli institutional and private investors, and thereafter in identifying and investing in mid/late stage Israeli based healthcare companies.
With a target of $350M to $450M, NGN II intends on committing 10% of the fund to investments in Israeli healthcare companies.
Gilad Lorberbaum will manage the joint operation with NGN on behalf of GlenRock Israel.
NGN II is a Venture Capital fund dedicated to Healthcare investing, focusing on ventures with the potential to achieve above average private equity returns with an emphasis on later stage investments. The Fund has flexibility to invest in a broad cross section of Healthcare and Biotechnology segments. The fund is diversified by stage, from later stage to selected early stage opportunities.
Read more about NGN Capital..
Yossi Gross
Yossi Gross is a seasoned entrepreneur with long-term successful experience in creating and managing new and innovative medical device companies in markets where there are significant unmet needs, ranging in stage from R&D through to commercialization.
Gross has founded and co-founded 14 medical device companies, among them: EMTI, VisionCare, BioControl, TransPharma, BrainsGate, Beta-02, EarlySense, G.I.View, ValTech, DuoCure and E-Pill.
Gross has filed over 200 US patents. In addition Mr.Gross is active as a medical device expert and executive and sits on the board of directors of more than 8 medical device start-up companies.
Previously, Gross served as a flight test engineer in the Israel Aircraft Industry and subsequently was part of the management team that developed the new Israeli LAVI fighter airplane.
Gross served as V.P. R&D at the multibillion dollar drug delivery company Elan Pharmaceutical, (NYSE:ELN).
Gross holds a degree in aeronautical engineering from the Israel Institute of Technology in Haifa and a degree in electrical engineering & bioengineering.
Recently Gross initiated Rainbow Medical with GlenRock an investment company aimed at generating significant returns from the realization of investments in early stage medical and bio devices companies, founded or seeded by Gross.
Efi Cohen-Arazi
Efi Cohen-Arazi has over twenty years of experience in the biotech/pharma industry in the areas of drug development and overall business and company management. He is currently the chairman of Rainbow Medical and executive chairman of Collplant, Israel and serves as board director in Kamada Israel and a few other biotech companies. Until July 2006, he was the CEO of Intec Pharma, an Israeli drug development company.
Previously, Cohen-Arazi worked at California-based Amgen Corporation for three years. At Amgen he was respectively Vice-President, Corporate Manufacturing, Head of Contract Manufacturing and VP & GM Site Head, Thousand Oaks, California. In his capacity as Head of the Contract Manufacturing Operations at Amgen, he established and led several strategic partnerships for development and manufacturing of small molecules and biopharmaceuticals.
Prior to working with Amgen, Cohen-Arazi was the Senior Vice President Operations at Immunex in Seattle, Washington where he developed and implemented strategies to ensure long term supply of Enbrel ® the company's blockbuster drug and managed an organization of more than 1000 people.
Cohen-Arazi worked for more than 12 years in a variety of leadership positions with the Serono Group in Switzerland and Israel and prior to that he was Plant Manager at ABIC Pharmaceutical Ltd.
Cohen-Arazi holds BSc and MSc degrees in Agriculture and Microbiology from the Hebrew University of Jerusalem.
Erez Diamant
Erez Diamant is a computer engineer who made his career in Hi-Tech business development and marketing. Among others, Erez was the Founder and CEO of Voltaire (NASDAQ: VOLT) and the VP of Marketing at Fundtech (NASDAQ: FNDT) and M-Systems (acquired for $ 1.55 Billion by SanDisk Corp.).
Erez also has an extensive background in Hi-Tech management consulting, stemming from the many years he served as a Managing Partner at POC - Israel's then leading management-consulting firm -- where he founded and led the Hi-Tech practice. In recent years he serves as a consultant to many Israeli start-ups and leading investment groups.
These days Erez is fascinated by the converged future of TV, Internet and advertising, serving - among others - as a Chairman of BestTV, providing emerging Video over Internet services with a comprehensive back-office software platform.
|
|
 |
|
 |
|
|
|
